Quidelortho Corp
F:QL1A

Watchlist Manager
Quidelortho Corp Logo
Quidelortho Corp
F:QL1A
Watchlist
Price: 24.4 EUR
Market Cap: €1.6B

Quidelortho Corp
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Quidelortho Corp
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Quidelortho Corp
F:QL1A
Research & Development
-$187.7m
CAGR 3-Years
-7%
CAGR 5-Years
-21%
CAGR 10-Years
-18%
Boston Scientific Corp
NYSE:BSX
Research & Development
-$2.1B
CAGR 3-Years
-16%
CAGR 5-Years
-12%
CAGR 10-Years
-9%
Stryker Corp
NYSE:SYK
Research & Development
-$1.6B
CAGR 3-Years
-8%
CAGR 5-Years
-10%
CAGR 10-Years
-10%
Abbott Laboratories
NYSE:ABT
Research & Development
-$2.8B
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
-8%
IDEXX Laboratories Inc
NASDAQ:IDXX
Research & Development
-$251.2m
CAGR 3-Years
0%
CAGR 5-Years
-12%
CAGR 10-Years
-10%
Intuitive Surgical Inc
NASDAQ:ISRG
Research & Development
-$1.3B
CAGR 3-Years
-15%
CAGR 5-Years
-18%
CAGR 10-Years
-21%
No Stocks Found

Quidelortho Corp
Glance View

Market Cap
1.6B EUR
Industry
Health Care

QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream. The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.

QL1A Intrinsic Value
59.75 EUR
Undervaluation 59%
Intrinsic Value
Price

See Also

What is Quidelortho Corp's Research & Development?
Research & Development
-187.7m USD

Based on the financial report for Sep 28, 2025, Quidelortho Corp's Research & Development amounts to -187.7m USD.

What is Quidelortho Corp's Research & Development growth rate?
Research & Development CAGR 10Y
-18%

Over the last year, the Research & Development growth was 19%. The average annual Research & Development growth rates for Quidelortho Corp have been -7% over the past three years , -21% over the past five years , and -18% over the past ten years .

Back to Top